Across TCGA pan-cancer cohorts, JADRR RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of JADRR’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where JADRR RNA is more highly expressed in tumor relative to normal tissue. In most cancer types JADRR is over-expressed in tumor.
LIHC are the cancer types where JADRR tumor–normal differential expression is most reproducible.